The Administration’s announcement that drug rebates violate federal anti-kickback rules is good news for people with diabetes. Rebates that drug companies provide make up about 70 percent of the list price of insulin, and ending their use in federally funded health care programs should make insulin more affordable for millions of Americans.

Now, the private sector must act. Today, JDRF calls for drug companies, as well as pharmacy benefit managers, health plans, and employers, to immediately end the use of rebates not only in federal programs but throughout the health system, and lower the list price of insulin accordingly. JDRF thanks the Administration for taking this important step to benefit the type 1 diabetes community and calls upon the Administration and Congress to continue to make affordable insulin a priority.

It is unconscionable for anyone to struggle to access insulin. Through its Coverage2Control campaign, JDRF has long advocated for more affordable insulin, including the end to the rebate system and other changes to improve coverage and lower out-of-pocket costs, and applauds efforts to ensure all those who need insulin can access this life-saving drug.

As JDRF fights for policies to make insulin more affordable for all, we are sharing information about programs to help with costs here as part of our insurance guide.